Roman-Ulrich Müller
@muellerrom.bsky.social did:plc:uo7jwenbaggd66sbdewtd3rp
passionate for translational research...kidney disease and beyond...
Bluesky’a katılma tarihi:
- Takipçi
- 108
- Takip edilen
- 21
- Post
- 82
- Sıralamaya girdiği gün
- 0
Özet
Roman-Ulrich Müller (@muellerrom.bsky.social), 27 Aralık 2024 tarihinde katılan bir Bluesky kullanıcısı. 108 takipçisi var, 21 hesabı takip ediyor ve 82 post paylaştı.
Sıralama geçmişi
Bu hesabın postlarının Debya günlük listesine girdiği en iyi günler.
Bu hesap henüz günlük sıralamaya girmedi.
Son beğendiği postlar
Bluesky ağındaki herkese açık beğeniler.
🧵 💙 There is no single way to live with PKD. For some, it may remain in the background for years; for others, it can shape everyday life, family, work, wellbeing and plans for the future.
Postu göster📊 Meta-analysis: In patients with cardiovascular disease, #HeartFailure, #ChronicKidneyDisease, or #diabetes, #SGLT2 inhibitors were associated with small increases in hemoglobin and hematocrit vs control. #KidneyWk @asnkidney.bsky.social ja.ma/4eLJwYo
Postu göster🚨 Publication Alert 🚨 #CRC1678 teamwork! New @nature.com paper spearheaded by @thevilchezlab.bsky.social in collaboration with Thorsten Hoppe reveals a cold‑induced BH2–BH4 pathway that boosts proteostasis and longevity. Great work! Congrats to everyone involved 🥳 👉 doi.org/10.1038/s415...
Postu göster1/7 ❄️ Very happy to share our new study: “Cold activates a BH2 metabolic network promoting longevity and proteostasis.” nature.com/articles/s41... #Aging #Longevity #Proteostasis #Metabolism #ALS #HuntingtonsDisease
Postu göster💻️💉 A research team led by Professor Dr Roman-Ulrich Müller has developed the digital platform MEDA-PKD. It links clinical follow-up data, laboratory results, imaging, information on medication and quality of life, initial molecular data on new biomarkers and other data. ➡️ uni.koeln/9YM53 #UniCologne
Postu göster
Blokladığı hesaplar
Bluesky’da bloklar herkese açık kayıtlardır.
Bu hesap kimseyi bloklamıyor.